Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
256
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.80 | 0.80 | -0.01% |
| CAC 40 | 8,121.49 | 46.66 | -0.57% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,367.06 | 94.87 | -0.20% |
| FTSE 100 | 9,918.84 | 21.87 | -0.22% |
| HKSE | 25,630.54 | 224.06 | -0.87% |
| NASDAQ | 23,419.08 | 55.27 | -0.24% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,896.24 | 9.50 | -0.14% |
| S&P/ASX 200 | 8,714.30 | 0.50 | -0.01% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |